U.S. HOT STOCK FUTURES: HOT STOCKS to WATCH

Among the companies with shares expected to actively trade in Monday's session are DSW Inc. (DSW), Infinity Pharmaceuticals Inc. (INFI) and Steel Dynamics Inc. (STLD.

Shoe retailer DSW projected weak fiscal second-quarter earnings, pointing to more clearance-priced sales as well as costs tied to its expansion plans. Shares slumped 11% to $52.07 in recent premarket trading.

Infinity is ending Phase 2 trials of its experimental drug, saridegib, to treat bone and cartilage cancers, saying results have been disappointing. Earlier this year, the company discontinued its Phase 2 studies of saridegib for the treatment of pancreatic cancer. Shares dropped 18% to $11.40 premarket.

Steel Dynamics forecast second-quarter earnings below analyst expectations, pointing to a decline in sheet-steel prices. Shares fell 4.2% to $10.56 premarket.

Women's accessories and apparel retailer Body Central Corp. (BODY) lowered its already disappointing forecast for the second quarter, citing soft sales. The company also reduced its full-year targets as same-store sales in the second quarter are now seen falling 7% to 9%. Shares slumped 23% to $12.40 in premarket trade.

 
   Watchlist: 
 

The Food and Drug Administration said its own analysis of compounded versions of the active ingredient in K-V Pharmaceuticals's (KVA, KVB) premature-birth prevention Makena drug did not identify any major safety problems, but reiterated that approved drugs are generally safer and more effective than compounded products.

Drug maker Merck & Co. (MRK) said a U.S. district court ruled against it in a patent-infringement suit involving Apotex Inc.

PetSmart Inc. (PETM) raised its quarterly dividend 18% and authorized a new $525 million share buyback, making the retailer for pet products the latest company to look to boost shareholder value.

Health-benefits provider WellPoint Inc. (WLP) said it will pay $90 million to resolve a lawsuit related to its initial public offering and lowered its full-year earnings projections.

 
   -Write to Mia Lamar at [e-mail]